Trial Profile
A Phase 3, Randomized, Controlled, Double-Masked, Multi-Center, Comparative, In Parallel Groups (For 24 Weeks), To Compare The Efficacy And Safety of 0.3 mg Pegaptanib Sodium, With Sham Injections, and Open Study (for 30 Weeks) to Confirm the Safety of 0.3 mg Pegaptanib Sodium in Subjects With Diabetic Macular Edema (Dme).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jul 2013
Price :
$35
*
At a glance
- Drugs Pegaptanib (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jun 2012 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 May 2012 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.